Xiaoyan Cai1, Xiong Liu2, Lichang Sun2, Yiting He2, Sulin Zheng2, Yang Zhang2, Yuli Huang2,3,4. 1. Department of Scientific Research and Education, Shunde Hospital, Southern Medical University, Foshan, China. 2. Department of Cardiology, Shunde Hospital, Southern Medical University, Foshan, China. 3. The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. 4. Guangdong Provincial Key Laboratory of Shock and Microcirculation, Southern Medical University, Guangdong, China.
Abstract
AIM: To determine the role of prediabetes in the incidence of heart failure (HF). MATERIALS AND METHODS: We searched electronic databases (PubMed, Embase, Google Scholar and OpenGrey) for studies up to 31 December 2020. Studies were included for meta-analysis if they reported adjusted relative risks (RRs) and 95% confidence intervals (CIs) for the risk of HF for prediabetes compared with normoglycaemia. Prediabetes was defined as impaired fasting glucose (IFG) according to the World Health Organization (WHO) criteria (IFG-WHO), or according to the American Diabetes Association (ADA) definition (IFG-ADA), impaired glucose tolerance (IGT), raised HbA1c according to the ADA criteria (HbA1c-ADA), or according to the International Expert Committee (IEC) recommendation (HbA1c-IEC). RESULTS: A total of 15 studies comprising 9,827,430 individuals provided data for this analysis. The median follow-up duration of the included studies was 8.0 years. Compared with normoglycaemia, prediabetes was associated with an increased risk for HF: IFG-ADA (RR: 1.09, 95% CI: 1.05-1.13), IFG-WHO (RR: 1.18, 95% CI: 1.07-1.30), IGT (RR 1.58, 95% CI 1.04-2.39), HbA1c-ADA (RR 1.28, 95% CI 1.16-1.41) or HbA1c-IEC (RR 1.40, 95% CI 1.09-1.79), respectively. CONCLUSIONS: Prediabetes is associated with an increased risk of HF. Future studies are needed to evaluate effective treatments for prediabetes to prevent the development and progression of HF.
AIM: To determine the role of prediabetes in the incidence of heart failure (HF). MATERIALS AND METHODS: We searched electronic databases (PubMed, Embase, Google Scholar and OpenGrey) for studies up to 31 December 2020. Studies were included for meta-analysis if they reported adjusted relative risks (RRs) and 95% confidence intervals (CIs) for the risk of HF for prediabetes compared with normoglycaemia. Prediabetes was defined as impaired fasting glucose (IFG) according to the World Health Organization (WHO) criteria (IFG-WHO), or according to the American Diabetes Association (ADA) definition (IFG-ADA), impaired glucose tolerance (IGT), raised HbA1c according to the ADA criteria (HbA1c-ADA), or according to the International Expert Committee (IEC) recommendation (HbA1c-IEC). RESULTS: A total of 15 studies comprising 9,827,430 individuals provided data for this analysis. The median follow-up duration of the included studies was 8.0 years. Compared with normoglycaemia, prediabetes was associated with an increased risk for HF: IFG-ADA (RR: 1.09, 95% CI: 1.05-1.13), IFG-WHO (RR: 1.18, 95% CI: 1.07-1.30), IGT (RR 1.58, 95% CI 1.04-2.39), HbA1c-ADA (RR 1.28, 95% CI 1.16-1.41) or HbA1c-IEC (RR 1.40, 95% CI 1.09-1.79), respectively. CONCLUSIONS:Prediabetes is associated with an increased risk of HF. Future studies are needed to evaluate effective treatments for prediabetes to prevent the development and progression of HF.
Authors: Nga Phi Thi Nguyen; Thuc Luong Cong; Binh Thanh Vu; Tuan Dinh Le; Thi Thanh Hoa Tran; Binh Nhu Do; Son Tien Nguyen; Lan Ho Thi Nguyen; Manh Van Ngo; Hoa Trung Dinh; Hoang Duong Huy; Nghia Xuan Vu; Kien Nguyen Trung; Duong Ngoc Vu; Nghia The Pham Journal: Int J Gen Med Date: 2022-03-08
Authors: Eduardo Thadeu de Oliveira Correia; Jeffrey I Mechanick; Letícia Mara Dos Santos Barbetta; Antonio José Lagoeiro Jorge; Evandro Tinoco Mesquita Journal: Heart Fail Rev Date: 2022-04-04 Impact factor: 4.214